Minimal clinically important difference in idiopathic pulmonary fibrosis

Area of Science:

• Pulmonary Medicine
• Clinical Trial Design
• Patient-Reported Outcomes

Background:

• Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with poor prognosis and significant quality of life (QoL) impact.
• Approved IPF treatments improve lung function decline but not QoL.
• Minimal Clinically Important Difference (MCID) quantifies meaningful changes for patients.

Purpose of the Study:

• To review MCID methodology and reported values in IPF.
• To highlight limitations in current MCID determination for IPF.
• To emphasize the need for patient-centered outcome measures in IPF research and care.

Main Methods:

• Literature review of MCID methodologies.
• Analysis of reported MCID values for physiological and patient-reported outcomes in IPF.
• Discussion of limitations in existing IPF MCID studies.

Main Results:

• MCID methodology lacks a gold standard.
• Commonly used anchors (e.g., death, hospitalization, PFTs) and distribution-based methods have limitations.
• Patient input is often inadequately incorporated into MCID determination in IPF.

Conclusions:

• Accurate MCID thresholds reflecting patient QoL are essential for IPF.
• Improved MCID determination will enhance clinical trial design and evaluation.
• Patient-oriented management algorithms for IPF require better outcome measure thresholds.